Literature DB >> 8504622

Statistical considerations in pharmacokinetic study design.

J D Powers1.   

Abstract

Pharmacokinetic studies may generally be categorised into 3 types: (a) population-based investigations, (b) individual-based compartmental, or (c) individual-based noncompartmental research projects. Each type of study has advantages and limitations. Population-based investigations pool drug concentrations across more than 1 individual subject. From these data, estimates of pharmacokinetic parameters are calculated. NONMEM is the only computer program available to evaluate this type of information. Recently a method has been proposed which derives individual estimates from the information available from NONMEM. By combining these 2 procedures it is possible for the clinician to review and adjust the dosage regimen if necessary. Population-based studies require fewer design criteria than other methods and are adaptable to the clinical setting, i.e. subjects can be patients currently being treated with the drug under consideration. One distinct advantage to this type of study is the flexibility of sampling times and the capability of the clinician to use information from the critically ill, the geriatric patient or the very young child. These subjects would not be available for the individual-based type of study because of the relatively large number of samples needed. Individual-based pharmacokinetic studies can be divided into 2 types with respect to their evaluation: (a) compartmental and (b) noncompartmental investigations. The latter type of study was originally thought to require fewer assumptions than the former but subsequently it has been shown that noncompartmental analyses are more restrictive and are basically compartmental in their approach. These studies estimate parameters which the compartmental investigation does not usually consider. These include area under the moment curve (AUMC) and mean residence time (MRT).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8504622     DOI: 10.2165/00003088-199324050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  23 in total

Review 1.  Statistical analysis of pharmacokinetic data.

Authors:  J Powers
Journal:  J Vet Pharmacol Ther       Date:  1990-06       Impact factor: 1.786

2.  An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.

Authors:  D B White; C A Walawander; Y Tung; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

5.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

6.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

7.  Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data.

Authors:  C C Peck; S L Beal; L B Sheiner; A I Nichols
Journal:  J Pharmacokinet Biopharm       Date:  1984-10

8.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

9.  Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

10.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04
View more
  6 in total

1.  Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.

Authors:  Evelyn D Lobo; Carol Robertson-Plouch; Tonya Quinlan; Quan Hong; Richard F Bergstrom
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

2.  Statistics or pharmacokinetics?

Authors:  V K Piotrovskij
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

Review 3.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

4.  Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.

Authors:  Francis E Lotrich; Robert Bies; Matthew F Muldoon; Stephen B Manuck; Gwenn S Smith; Bruce G Pollock
Journal:  Psychopharmacology (Berl)       Date:  2004-09-09       Impact factor: 4.530

5.  The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery.

Authors:  Alexandra Douglas; Mahdi Altukroni; Andrew A Udy; Michael S Roberts; Kersi Taraporewalla; Jason Jenkins; Jeffrey Lipman; Jason A Roberts
Journal:  BMC Anesthesiol       Date:  2011-02-22       Impact factor: 2.217

6.  Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study.

Authors:  Dwarakanathan Ranganathan; Julie M Varghese; Robert G Fassett; Jeffrey Lipman; Vincent D'Intini; Helen Healy; Jason A Roberts
Journal:  BMC Nephrol       Date:  2009-12-16       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.